Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

EPS and iPS Cells in Disease Research

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Interstitial granulomatous dermatitis and palisaded neutrophilic granulomatous dermatitis.

Cutis·2018

Same author

Sacral zoster with a primary complaint of difficulty voiding.

JAAD case reports·2018

Same author

Nuclear factor XIIIa staining (clone AC-1A1 mouse monoclonal) is a sensitive and specific marker to discriminate sebaceous proliferations from other cutaneous clear cell neoplasms.

Journal of cutaneous pathology·2016

Same author

Nuclear factor XIIIa staining (clone AC-1A1 mouse monoclonal) is a highly sensitive marker of sebaceous differentiation in normal and neoplastic sebocytes.

Journal of cutaneous pathology·2016

Same author

Characterization of dermatopathology fellowship applicants: a 5-year single institution experience.

Journal of cutaneous pathology·2016

Same author

A survey of self-reported skin disease in the elderly African-American population.

International journal of dermatology·2014

Search research articles

Related Experiment Video

Updated: May 31, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Ustekinumab: differential use in psoriasis.

Elizabeth E Uhlenhake¹, David A Mehregan

¹Wayne State University Department of Dermatology, Wayne State University School of Medicine, Detroit, MI, USA.

Clinical, Cosmetic and Investigational Dermatology

|July 16, 2011

Summary

Ustekinumab offers a new treatment option for chronic plaque psoriasis patients seeking better results. While effective, its long-term safety profile requires further study for informed prescribing decisions.

Keywords:

biologics psoriasis safety treatment ustekinumab

Related Experiment Videos

Last Updated: May 31, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Area of Science:

Immunodermatology
Systemic autoimmune diseases

Background:

Chronic plaque psoriasis affects over 3% of the population.
Many patients remain unsatisfied with existing psoriasis treatments.
Advances in understanding psoriasis pathophysiology drive new therapeutic development.

Purpose of the Study:

To summarize current psoriasis treatment options.
To provide an overview of ustekinumab, a novel biologic agent.
To aid prescribers in making informed treatment decisions.

Main Methods:

Literature review of psoriasis pathophysiology and treatments.
Analysis of available data on ustekinumab efficacy and safety.
Comparison of ustekinumab with other biologic therapies.

Main Results:

Ustekinumab demonstrates rapid results and convenient dosing (four annual subcutaneous administrations).
Its efficacy and safety profiles are comparable to existing biologics.
Long-term adverse event data for ustekinumab are still emerging.

Conclusions:

Ustekinumab represents a significant advancement in psoriasis therapy.
Prescribers need comprehensive data to guide ustekinumab use.
Further post-market surveillance is essential to fully understand ustekinumab's safety profile.